Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models

Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models

Dysregulation of hepatic lipid and cholesterol metabolism is a significant contributor to cardiometabolic health, resulting in excessive liver lipid accumulation and ultimately non-alcoholic steatohepatitis (NASH). Therapeutic activators of the AMP-Activated Protein Kinase (AMPK) have been proposed...

Full description

Bibliographic Details
Main Authors: Ryan M. Esquejo, Christopher T. Salatto, Jake Delmore, Bina Albuquerque, Allan Reyes, Yuji Shi, Rob Moccia, Emily Cokorinos, Matthew Peloquin, Mara Monetti, Jason Barricklow, Eliza Bollinger, Brennan K. Smith, Emily A. Day, Chuong Nguyen, Kieran F. Geoghegan, John M. Kreeger, Alan Opsahl, Jessica Ward, Amit S. Kalgutkar, David Tess, Lynne Butler, Norimitsu Shirai, Timothy F. Osborne, Gregory R. Steinberg, Morris J. Birnbaum, Kimberly O. Cameron, Russell A. Miller
Format: Article
Language:English
Published: Elsevier 2018-05-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396418301373

Internet

http://www.sciencedirect.com/science/article/pii/S2352396418301373

Similar Items